Table 2.

Respondents’ general knowledge on the safety of conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications in the management of inflammatory arthritis in pregnancy

	Safe throughout pregnancy (% of respondents)	Safe during certain trimesters (% of respondents)	Not safe at all (% of respondents)	Not sure (% of respondents)
Conventional synthetic disease modifying anti-rheumatic drugs
Azathioprine	80.5*	4.9	12.2	2.4
Chloroquine	74.1	1.2	8.6	16.0
Cyclophosphamide	0	3.7	95.1*	1.2
Cyclosporine	28.0	6.1	42.7	23.2
Doxycycline	2.4	4.9	59.8	32.9
Gold salts	28.7	2.5	33.8	35.0
Hydroxychloroquine	92.7*	4.9	1.2	1.2
Leflunomide	0	0	97.6*	2.4
Methotrexate	0	1.2	97.6*	1.2
Minocycline	0	4.9	53.1	42.0
Mycophenolate mofetil	2.5	2.5	81.5*	13.6
Sulfasalazine	70.4	8.6	18.5	2.5
Biologics/small molecules
Abatacept	9.8	9.8	15.9	64.6
Adalimumab	37.0	32.1	6.2	24.7
Anakinra	9.9	6.2	16.0	67.9
Apremilast	0	1.2	18.5	80.2*
Certolizumab	61.0	15.9	4.9	18.3
Etanercept	43.9	29.3	7.3	19.5
Golimumab	37.8	25.6	11.0	25.6
Infliximab	37.8	30.5	8.5	23.2
Rituximab	8.5	8.5	25.6	57.3
Tocilizumab	11.0	8.5	19.5	61.0
Tofacitinib	1.2	1.2	21.0	76.5*
Ustekinumab	4.9	6.1	18.3	70.7
Other medications
Celecoxib	0	54.9	29.3	15.9
Ibuprofen	1.2	83.6*	14.5	1.2
Naproxen	2.4	82.9*	11.0	3.7
Other NSAIDs	1.2	67.5	22.5	8.8

*Indicates consensus among respondents based on a priori cut-off of ≥75%